IRWD vs BGM โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
IRWD Captures Institutional Edge (3โ1 Pillars ยท 6โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Ironwood Pharmaceuticals, Inc. - Class A (IRWD) driven by superior Valuation, Growth & Margin, Options & Structure while BGM counters with relative strength in Momentum & Technical. Fundamentally, IRWD trades at 12.3x Forward P/E with 62.9% operating margin (+9.0% YoY revenue) versus BGM at N/M Forward P/E and -23.4% operating margin (+69.8% YoY). In options structure, IRWD sits in CONSOLIDATION (30th %ile IV; Dealer Gamma Walls on Pro) against BGM sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | IRWD | BGM | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $779.7M | $108.6M | Larger Scale | IRWD |
| Trailing P/E Ratio Valuation | 5.2x | N/M | Lower Multiple | IRWD |
| Forward P/E Ratio Valuation | 12.3x | N/M | Lower Multiple | IRWD |
| Revenue Growth (YoY) Growth | +9.0% | +69.8% | Higher Growth | BGM |
| Operating Margin (TTM) Profitability | 62.9% | -23.4% | Higher Margin | IRWD |
| Net Profit Margin Profitability | 37.4% | -44.2% | Higher Margin | IRWD |
| Return on Equity (ROE) Capital Efficiency | -574.7% | -7.4% | Higher ROE | BGM |
| 52-Week Range Position Momentum | 62% ($3โ$6) | 74% ($0โ$11) | Stronger Trend | BGM |
| Beta / 30D Volatility Risk Regime | 1.23ฮฒ ยท 54% Vol | 3.69ฮฒ ยท 80% Vol | Lower Realized Risk | IRWD |
| Unified Institutional Score Composite Signal | 37.8 / 100 (SELL) | 59.6 / 100 (HOLD) | Higher Composite | BGM |